These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35669725)

  • 1. A Multiomics Profiling Based on Online Database Revealed Prognostic Biomarkers of BLCA.
    Li H; Chen S; Mi H
    Biomed Res Int; 2022; 2022():2449449. PubMed ID: 35669725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer.
    Li H; Zhang Y; Zheng S
    Biomed Res Int; 2021; 2021():8530186. PubMed ID: 34926692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
    Chen F; Wang Q; Zhou Y
    BMC Cancer; 2021 Mar; 21(1):244. PubMed ID: 33685397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
    Hu J; Wang L; Li L; Wang Y; Bi J
    BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Immune-Related Subtypes and Construction of a Novel Prognostic Model for Bladder Urothelial Cancer.
    Zhang J; Huang C; Yang R; Wang X; Fang B; Mi J; Yuan H; Mo Z; Sun Y
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
    Li C; Wan Z; Deng Q; Li Z; Wang Y
    Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
    Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
    Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of hub genes associated with bladder cancer using bioinformatic analyses.
    Zheng W; Zhao Y; Wang T; Zhao X; Tan Z
    Transl Cancer Res; 2022 May; 11(5):1330-1343. PubMed ID: 35706790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
    Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
    Front Immunol; 2023; 14():955949. PubMed ID: 37006317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma.
    Mi Y; Wang X
    J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Three Protein-Coding Gene Prognostic Model Predicts Overall Survival in Bladder Cancer Patients.
    Ning XH; Qi YY; Wang FX; Li SC; Jia ZK; Yang JJ
    Biomed Res Int; 2020; 2020():7272960. PubMed ID: 33150179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
    Xing P; Jiang Z; Liu Y
    BMC Cancer; 2022 Aug; 22(1):926. PubMed ID: 36030212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of hexosamine biosynthesis pathway as a novel prognostic signature and its correlation with immune infiltration in bladder cancer.
    Cui Y; Feng H; Liu J; Wu J; Zhu R; Huang R; Yan J
    Front Mol Biosci; 2022; 9():1009168. PubMed ID: 36158580
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel anoikis-related gene signature identifies LYPD1 as a novel therapy target for bladder cancer.
    Song Z; Gui S; Xiao S; Rao X; Cong N; Deng H; Yu Z; Zeng T
    Sci Rep; 2024 Feb; 14(1):3198. PubMed ID: 38332160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical analysis of novel prognostic transcription factors and immune-related gene signatures for bladder cancer via TCGA-based bioinformatic analysis.
    Deng Y; Hong X; Yu C; Li H; Wang Q; Zhang Y; Wang T; Wang X
    Oncol Lett; 2021 May; 21(5):344. PubMed ID: 33747201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.